(NASDAQ: MREO) Mereo Biopharma Group's forecast annual revenue growth rate of 507.11% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 89.16%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.7%.
Mereo Biopharma Group's revenue in 2025 is $500,000.On average, 2 Wall Street analysts forecast MREO's revenue for 2025 to be $51,706,486,260, with the lowest MREO revenue forecast at $40,171,962,402, and the highest MREO revenue forecast at $63,241,010,118. On average, 2 Wall Street analysts forecast MREO's revenue for 2026 to be $67,178,657,918, with the lowest MREO revenue forecast at $60,138,620,942, and the highest MREO revenue forecast at $74,218,694,893.
In 2027, MREO is forecast to generate $90,271,570,166 in revenue, with the lowest revenue forecast at $70,766,292,580 and the highest revenue forecast at $109,776,847,752.